Search Results

You are looking at 61 - 70 of 369 items for :

  • "therapeutics" x
  • Refine by Access: All x
Clear All
Full access

Updates to the Management of Patients With Relapsed or Refractory Indolent Follicular and Marginal Zone Lymphomas

Presented by: Ann S. LaCasce and Ariela Noy

Therapeutics announced the voluntary withdraw of umbralisib (UKONIQ) from sale for the approved indications of adult patients with MZL who have received at least one prior anti-CD20–based regimen and for adult patients with FL who have received at least 3 prior

Full access

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, Asher A. Chanan-Khan, Julio C. Chavez, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Shuo Ma, Sami Malek, Anthony Mato, Claudio Mosse, Vishala T. Neppalli, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Mary A. Dwyer, and Hema Sundar

/research support from AbbVie, Inc.; Acerta Pharma, LLC; Cyclacel Pharmaceuticals, Inc.; Gilead Sciences, Inc.; Intrexon Corporation; Juno Therapeutics, Inc.; Kite Pharma, Inc.; Oncternal Therapeutics; Precigen, Inc.; Xencor, Inc.; Pharmacyclics, Inc.; Roche

Full access

Communicating Treatment Options to Older Patients: Challenges and Opportunities

Arti Hurria

of new therapeutics. Although oncology therapeutics undergo a stringent approval process under FDA regulations, older adults are inexplicably under-represented in registration trials. As of 1993, federal law has mandated that the NIH include and

Full access

Systemic Management of Colorectal Cancer

Wells A. Messersmith

“You really can't treat colorectal cancer [CRC] today without molecular testing,” remarked Wells A. Messersmith, MD, Co-Director of the Developmental Therapeutics Program, University of Colorado Cancer Center, and Professor of Medicine, Director

Full access

Active Systemic Treatment of Pancreatic Cancer

Margaret Tempero

Biotech Resources, LLC, NeoHealth Inc., Novocure, Opsona Therapeutics, Portola Pharmaceuticals, Inc., and Threshold Pharmaceuticals Inc.; and grant/research support from Celgene Corporation and Halozyme Therapeutics, Inc.; and she has served as a

Full access

NCCN Guidelines: Pretransplant Recipient Evaluation and Management of Graft-Versus-Host Disease

Corey Cutler and Steven Z. Pavletic

clinical management have not changed, though they have become more complicated with the development and even FDA approval of new drugs for this indication. Similarly, use of HCT has shifted with the development of novel therapeutics in leukemia and lymphoma

Full access

NCCN Guidelines Updates: Management of Metastatic Colorectal Cancer

Wells A. Messersmith

Guidelines regarding BRAF . Abbreviation: mAb, monoclonal antibody. Disclosures: Dr. Messersmith has disclosed that he receives institutional grant/research support from Alexo Therapeutics, Inc.; D3 Pharma; Genentech, Inc.; Immunomedics; Incyte; Millennium

Full access

Advances in the Care of Adult Patients With Acute Lymphoblastic Leukemia: Optimism Tempered by Reality

Joseph C. Alvarnas and Patrick A. Brown

new classes of antileukemia drugs and cellular therapeutics are fast becoming part of our ALL care strategy. These include therapeutics targeted at the expanding list of tumor-specific gene mutations and rearrangements that characterize the novel “Ph

Full access

Primary Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer in Asia: Unique or Not?

Masaki Shiota

expectancy <10 years was challenged. This study has several limitations. First, the data on diagnosis, therapeutics, and outcome are very limited, and Gleason score, prostate-specific antigen level at diagnosis, detailed clinical stage and modality used for

Full access

NCCN's Commitment to Medication Safety: The Vincristine Initiative

Jessica Sugalski, F. Marc Stewart, and Robert W. Carlson

set a goal to ensure that all NCCN Member Institutions would follow this recommended policy. Accordingly, NCCN sent information outlining the recommended policy, the rationale for the policy, and relevant references to the Pharmacy & Therapeutics